STOCK TITAN
  1. Home
  2. Sec-filings
  3. MEOBF
  4. [6-K] MESOBLAST LTD Current Report (Foreign Issuer)

CAR platform expands Mesoblast (MEOBF) cell therapy pipeline reach

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Mesoblast Limited reported that it has acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform designed to enhance its mesenchymal stromal cell (MSC) therapies. The CAR constructs are intended to improve targeted homing of MSCs to inflamed tissues, aiming to increase potency in inflammatory and autoimmune diseases.

The intellectual property, originally developed at Mayo Clinic and published in Nature Biomedical Engineering, may support new or stronger indications such as ulcerative colitis, Crohn's disease, Lupus Nephritis and other B cell–driven conditions. Mesoblast obtained the rights via acquiring a startup formed to advance the CAR-MSC technology, paying with ASX ordinary shares, and Mayo Clinic will provide in-kind support including GMP manufacturing activities.

Positive

  • None.

Negative

  • None.
Patent portfolio size Over 1,000 patents/applications Global IP covering MSC compositions, manufacturing and indications
IP protection horizon Through at least 2044 Commercial protection in all major markets for MSC-related patents
Pediatric eligibility for Ryoncil 2 months and older FDA-approved indication for SR-aGvHD in pediatric patients
Nature Biomedical Engineering reference year 2024 Publication year of foundational CAR-MSC research cited
chimeric antigen receptor (CAR) technology medical
"acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform"
mesenchymal lineage stromal cell (MSC) products medical
"for precision-enhanced augmentation of therapeutic mesenchymal lineage stromal cell (MSC) products"
Lupus Nephritis medical
"use CAR-MSC engineered to express CD19 on their surface to induce remission in Lupus Nephritis"
Lupus nephritis is a condition in which a person’s immune system attacks the kidneys, causing inflammation and damage to the organs’ filtering function and leading to blood or protein in the urine and, in severe cases, kidney failure. For investors, it defines a specific, medically serious patient group and treatment need: success or failure of therapies, clinical trials, regulatory approvals, and pricing decisions for drugs aimed at this condition can meaningfully change a biotech or pharma company’s revenue prospects — like fixing a costly, central leak in a building that determines the value of the whole property.
steroid-refractory acute graft versus host disease (SR-aGvHD) medical
"Ryoncil ... for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients"
allogeneic (off-the-shelf) cellular medicines medical
"a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe"
forward-looking statements regulatory
"This press release includes forward-looking statements that relate to future events or our future financial performance"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
For the month of April 2026
Commission File Number 001-37626
Mesoblast Limited
(Exact name of Registrant as specified in its charter)
Not Applicable
(Translation of Registrant’s name into English)
Australia
(Jurisdiction of incorporation or organization)

Silviu Itescu
Chief Executive Officer and Executive Director
Level 38
55 Collins Street
Melbourne 3000
Australia
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:
Form 20-F ☑ Form 40-F ☐




INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K
On April 15, 2026, Mesoblast Limited filed with the Australian Securities Exchange a new release announcement, which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

Mesoblast Limited
/s/ Paul Hughes
Paul Hughes
Company Secretary
Dated: April 15, 2026


INDEX TO EXHIBITS
Item
 99.1
Press release of Mesoblast Ltd, dated April 15, 2026.




MESOBLAST ACQUIRES CHIMERIC ANTIGEN RECEPTOR (CAR) PLATFORM TECHNOLOGY FOR PRECISION-ENHANCED CELL PRODUCTS New York, USA: April 14 and Melbourne, Australia: April 15, 2026: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform for precision-enhanced augmentation of therapeutic mesenchymal lineage stromal cell (MSC) products. Mesoblast plans to incorporate the engineered CARs to further boost effectiveness of Mesoblast's products, with the goal of enhancing the target specificity and augmenting inherent properties of immunomodulation and tissue regeneration. Mesoblast’s MSC technology platforms, including the first and only FDA-approved MSC product in the U.S., are designed for the treatment of tissue-specific inflammatory diseases due to their inherent homing capabilities and immunomodulatory properties. The aim of genetically engineering CAR constructs into MSCs is to substantially enhance targeted homing to inflamed tissue resulting in greater potency. The foundational work on the CAR technology was developed by investigators at Mayo Clinic and published in Nature Biomedical Engineering.1 The investigators identified various CAR-MSCs with potential for enhanced tissue-specific targeting in inflammatory and autoimmune diseases, including to inflamed bowel. This provides Mesoblast with an immediate opportunity to generate products with even greater potency for ulcerative colitis or Crohn's disease. In addition, Mesoblast plans to use CAR-MSC engineered to express CD19 on their surface to induce remission in Lupus Nephritis and other B cell autoimmune diseases where durable, effective and safe immunomodulation is highly desirable. Mesoblast obtained the worldwide exclusive rights to the CAR-MSC intellectual property developed at Mayo Clinic through the acquisition of a startup formed specifically to advance the technology. As part of the exclusive license, Mayo Clinic will provide in-kind support geared toward further advancing the technology and resulting products, including GMP manufacturing activities. The acquisition was accomplished by Mesoblast through the issuance of ASX ordinary shares. Silviu Itescu, Chief Executive of Mesoblast, said: "This innovative genetic modification technology fits well with our strategy to extend our market leadership by creating products with even greater efficacy and new target indications." About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com. Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. Exhibit 99.1

 

About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets. About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast Note Mayo Clinic has a financial interest in the technology referenced in this press release through a license agreement with Mesoblast. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research. References/Footnotes 1. Sirpilla, O. et al. Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression. Nat Biomed Eng. 2024 April; 8(4): 443–460. Forward-Looking Statements This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive.

 

For more information, please contact: Corporate Communications / Investors Paul Hughes T: +61 3 9639 6036 Media – Global Media – Australia Rubenstein BlueDot Media Caroline Nelson Steve Dabkowski T: +1 703 489 3037 T: +61 419 880 486 E: cnelson@rubenstein.com E: steve@bluedot.net.au

 

Source: View Original Filing on SEC EDGAR

FAQ

What did Mesoblast (MEOBF) announce in its latest 6-K filing?

Mesoblast announced it acquired an exclusive worldwide license to a patented CAR technology platform for engineered mesenchymal stromal cells. The goal is to enhance targeting and potency of its cell therapies for inflammatory and autoimmune diseases, expanding its existing MSC-based treatment portfolio.

How did Mesoblast (MEOBF) obtain the CAR-MSC technology rights?

Mesoblast obtained worldwide exclusive rights to the CAR-MSC intellectual property by acquiring a startup formed specifically to advance the technology. The transaction was completed through the issuance of ASX ordinary shares, aligning ownership with the company’s equity rather than using cash consideration.

Which diseases could Mesoblast’s new CAR-MSC platform target?

The CAR-MSC platform is intended to enhance tissue-specific targeting in inflammatory and autoimmune diseases. Examples mentioned include inflammatory bowel conditions such as ulcerative colitis and Crohn's disease, as well as Lupus Nephritis and other B cell–mediated autoimmune disorders requiring durable immunomodulation.

What role does Mayo Clinic play in Mesoblast’s CAR technology deal?

Mayo Clinic investigators developed the foundational CAR-MSC work and published it in Nature Biomedical Engineering. Under the exclusive license, Mayo Clinic will provide in-kind support to Mesoblast, including activities such as GMP manufacturing, and will use any related revenue to support its not-for-profit mission.

What existing FDA-approved product does Mesoblast (MEOBF) highlight?

Mesoblast highlights Ryoncil (remestemcel-L-rknd), described as the first FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in pediatric patients two months and older. The company is also developing Ryoncil for additional inflammatory diseases and expanding its stromal cell platforms.

How strong is Mesoblast’s intellectual property position in MSC therapies?

Mesoblast reports a global intellectual property portfolio of over 1,000 granted patents or applications covering MSC compositions, manufacturing and indications. These rights provide commercial protection extending through at least 2044 in major markets, supporting long-term exclusivity around its mesenchymal stromal cell technology platforms.

Filing Exhibits & Attachments

1 document

Press Releases